Associated Papers
Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients With Acute Myeloid Leukemia Receiving Delayed-Release Tablets.
Parant F et al.
Therapeutic Drug Monitoring, 2025
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
Šušak Sporiš I et al.
Fundamental & Clinical Pharmacology, 2024
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Božina N et al.
European Journal of Clinical Pharmacology, 2023
Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzì Brancati V et al.
International Journal of Molecular Sciences, 2023
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML et al.
Pharmacological Research, 2021
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Ortega-Vázquez A et al.
The Pharmacogenomics Journal, 2020
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I et al.
British Journal of Clinical Pharmacology, 2018
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N et al.
Clinical Pharmacokinetics, 2016
Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
Wang Q et al.
Drug Metabolism and Pharmacokinetics, 2015
A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.
Greer AK et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO et al.
Breast Cancer Research and Treatment, 2014
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO et al.
Breast Cancer Research and Treatment, 2013
Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.
Edavana VK et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population.
Yang J et al.
Plos One, 2012
A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.
Benoit-Biancamano MO et al.
Pharmacogenetics and Genomics, 2009
Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population.
Yea SS et al.
Therapeutic Drug Monitoring, 2008
Genetic variations and haplotypes of UGT1A4 in a Japanese population.
Saeki M et al.
Drug Metabolism and Pharmacokinetics, 2005